Q1-2021 was Evofem's second full quarter of product sales, totaling $1.1 million. This followed the U.S. commercial launch of Phexxi on September 8, 2020.
Would it be crazy to see sales at $5 mil....
They are going all out--> marketing costs were $30.5 million
Think how mad you would be as an investor..
For investors, the company had sold $25 million of unsecured convertible promissory notes to Adjuvant Capital back in October 2020. The notes are convertible into shares of Evofem common stock at a conversion price
of $3.65 per share, with proceeds from the sale to be used to support EVOGUARD and expand global market access for Phexxi gel. Additionally, in April, Evofem raised $4.2 million in net proceeds.<-- That's a good deal!
Then, there was yet another $50 million public offering on May 17, with the
shares plummeting by 35.7% the next day. -- just five days earlier (on May 12) the U.S. Food and Drug Administration (FDA) granted fast track designation to EVO100.<---
That's what we are awaiting the Trial for...
10.1%stake by Morgan Stanley (
MS), Evofem Are they still in?
with no FDA-approved prescription products to prevent
gonorrhea, a sexually transmissible disease, there is significant opportunity for Evofem, as according to a
new reportpublished by the Centers for Disease Control and Prevention, more than 600,000 cases of gonorrhea were reported in 2019, representing an increase for the sixth consecutive year.
Yup Young & Fun...
Saundra Pelletier
CEO / President
Saundra Pelletier is the Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc. --multiple equity financing rounds that have raised in excess of $245 million. It is her vision and the Company’s mission to address the unmet sexual and reproductive health needs of women.
Jay File- Common' It's just a hug
Chief Financial Officer
Jay File serves as theChief Financial Officerof Evofem Biosciences.
Kelly Culwell- I'm not scary!
Chief Medical Officer
Kelly Culwell serves as theChief Medical Officerof Evofem Biosciences.
